Literature DB >> 19395448

Lupus and cancer.

M Gayed1, S Bernatsky, R Ramsey-Goldman, Ae Clarke, C Gordon.   

Abstract

Individuals with systemic lupus erythematosus (SLE) have an increased susceptibility to certain types of cancer. Of particular concern are haematologic malignancies, specifically non-Hodgkin lymphoma, where a three- to four-fold increased risk is seen in SLE, compared with the general population. There is some evidence that immunosuppressive exposures play a role, although there appear to be other factors driving the risk. Lupus disease activity, with resultant dysregulated lymphocyte proliferation, may itself be a mediator of the association between SLE and lymphoma. Aside from haematologic malignancy risk, lung cancer also is increased in SLE compared with the general population, and smoking likely drives this risk in large part. Last but not least, cervical dysplasia is a concern in women with SLE, particularly with exposure to immunosuppressants; routine screening for this complication should not be neglected.

Entities:  

Mesh:

Year:  2009        PMID: 19395448     DOI: 10.1177/0961203309102556

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  29 in total

1.  MHC class I family proteins retard systemic lupus erythematosus autoimmunity and B cell lymphomagenesis.

Authors:  Caroline G McPhee; Thomas J Sproule; Dong-Mi Shin; Jason A Bubier; William H Schott; Martin P Steinbuck; Lia Avenesyan; Herbert C Morse; Derry C Roopenian
Journal:  J Immunol       Date:  2011-09-30       Impact factor: 5.422

2.  Systemic lupus erythematosus and malignancies risk.

Authors:  Song Mao; Hua Shen; Jianhua Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-29       Impact factor: 4.553

Review 3.  Systemic lupus erythematosus and increased risk to develop B cell malignancies: role of the p200-family proteins.

Authors:  Sudhakar Veeranki; Divaker Choubey
Journal:  Immunol Lett       Date:  2010-06-26       Impact factor: 3.685

4.  The NBS1 genetic polymorphisms and the risk of the systemic lupus erythematosus in Taiwanese patients.

Authors:  Ying-Ju Lin; Yu-Ching Lan; Lei Wan; Chung-Ming Huang; Cheng-Wen Lin; Kai-Chung Hsueh; Da-Yuan Chen; Ting-Hsu Lin; Fuu-Jen Tsai
Journal:  J Clin Immunol       Date:  2010-06-23       Impact factor: 8.317

5.  Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study.

Authors:  Shir Azrielant; Shmuel Tiosano; Abdulla Watad; Naim Mahroum; Aaron Whitby; Doron Comaneshter; Arnon D Cohen; Howard Amital
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

6.  Increased expression of human T-cell immunoglobulin- and mucin-domain-containing molecule-4 in peripheral blood mononuclear cells from patients with system lupus erythematosus.

Authors:  Peiqing Zhao; Liyun Xu; Piming Wang; Xiaohong Liang; Jianni Qi; Peng Liu; Chun Guo; Lining Zhang; Chunhong Ma; Lifen Gao
Journal:  Cell Mol Immunol       Date:  2010-02-08       Impact factor: 11.530

7.  Malignancies associated with systemic lupus erythematosus in Taiwan: a nationwide population-based cohort study.

Authors:  Ji-An Liang; Li-Min Sun; Jun-Jun Yeh; Wan-Yu Lin; Shih-Ni Chang; Hung-Chang Sung; Chia-Hung Kao
Journal:  Rheumatol Int       Date:  2010-12-31       Impact factor: 2.631

8.  AID dysregulation in lupus-prone MRL/Fas(lpr/lpr) mice increases class switch DNA recombination and promotes interchromosomal c-Myc/IgH loci translocations: modulation by HoxC4.

Authors:  Clayton A White; J Seth Hawkins; Egest J Pone; Elliot S Yu; Ahmed Al-Qahtani; Thach Mai; Hong Zan; Paolo Casali
Journal:  Autoimmunity       Date:  2011-05-18       Impact factor: 2.815

9.  Malignancy in scleroderma patients from south west England: a population-based cohort study.

Authors:  Keith Siau; C J Laversuch; P Creamer; K P O'Rourke
Journal:  Rheumatol Int       Date:  2010-01-08       Impact factor: 2.631

10.  Novel estrogen target gene ZAS3 is overexpressed in systemic lupus erythematosus.

Authors:  Nicholas A Young; Alexandra K Friedman; Benjamin Kaffenberger; Murugesan V S Rajaram; Daniel J Birmingham; Brad H Rovin; Lee A Hebert; Larry S Schlesinger; Lai-Chu Wu; Wael N Jarjour
Journal:  Mol Immunol       Date:  2012-11-22       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.